Pathologic response and survival after cisplatin, pemetrexed, and bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer

被引：0
|
作者：
Tsutani, Y. [1 ]
Miyata, Y. [1 ]
Suzuki, K. [2 ]
Takamochi, K. [2 ]
Tanaka, F. [3 ]
Nakayama, H. [4 ]
Yamashita, Y. [5 ]
Oda, M. [6 ]
Tsuboi, M. [7 ]
Okada, M. [1 ]
机构：
[1] Hiroshima Univ, Surg Oncol, Hiroshima, Japan
[2] Juntendo Univ, Gen Thorac Surg, Sch Med, Tokyo, Japan
[3] Univ Occupat & Environm Hlth, Thorac Surg, Kitakyushu, Fukuoka, Japan
[4] Kanagawa Canc Ctr, Thorac Surg, Yokohama, Kanagawa, Japan
[5] Chugoku Canc Ctr, Kure Med Ctr, Thorac Surg, Kure, Japan
[6] Kanazawa Univ, Thorac Surg, Kanazawa, Ishikawa, Japan
[7] Natl Canc Ctr Hosp East, Thorac Surg & Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw382.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1197P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pathologic response to predict survival in patients who underwent surgery after neoadjuvant chemotherapy with bevacizumab for clinical stage II/IIIA non-squamous non-small cell lung cancer.
    Tsutani, Yasuhiro
    Kai, Yuichiro
    Ito, Masaoki
    Mimura, Takeshi
    Miyata, Yoshihiro
    Suzuki, Kenji
    Takamochi, Kazuya
    Tanaka, Fumihiro
    Nakayama, Haruhiko
    Yamashita, Yoshinori
    Oda, Makoto
    Tsuboi, Masahiro
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: Survival results from a phase II feasibility study (NAVAL)
    Tsutani, Y.
    Miyata, Y.
    Suzuki, K.
    Takamochi, K.
    Tanaka, F.
    Nakayama, H.
    Yamashita, Y.
    Oda, M.
    Tsuboi, M.
    Okada, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Tanijiri, Tsutomu
    Ogata, Makoto
    Inagaki, Noriko
    Kibata, Kayoko
    Hayashi, Mina
    Niki, Maiko
    Shimizu, Toshiki
    Miyara, Takayuki
    Kurata, Takayasu
    Nomura, Shosaku
    ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457
  • [4] Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Fukushima, Toshirou
    Wakatsuki, Yuuki
    Kobayashi, Takashi
    Sonehara, Kei
    Tateishi, Kazunari
    Yamamoto, Manabu
    Masubuchi, Takeshi
    Yoshiike, Fumiaki
    Hirai, Kazuya
    Hachiya, Tsutomu
    Koizumi, Tomonobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1043 - 1050
  • [5] Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Toshirou Fukushima
    Yuuki Wakatsuki
    Takashi Kobayashi
    Kei Sonehara
    Kazunari Tateishi
    Manabu Yamamoto
    Takeshi Masubuchi
    Fumiaki Yoshiike
    Kazuya Hirai
    Tsutomu Hachiya
    Tomonobu Koizumi
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1043 - 1050
  • [6] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
    Guarino, Michael J.
    Masters, Gregory A.
    Biggs, David D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
  • [7] Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
    Kondo, T.
    Kasai, T.
    Mori, K.
    Saito, H.
    Nishikawa, K.
    Otsu, S.
    Seki, N.
    Ichikawa, Y.
    Bessho, A.
    Tanaka, H.
    Yamaguchi, H.
    Kaburagi, T.
    Kanazawa, K.
    Komase, Y.
    Minato, K.
    Misumi, Y.
    Morinaga, R.
    Mori, K.
    Ohtake, J.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S875 - S875
  • [8] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [9] Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
    Tsutani, Y.
    Miyata, Y.
    Masuda, T.
    Fujitaka, K.
    Doi, M.
    Awaya, Y.
    Kuyama, S.
    Kitaguchi, S.
    Ueda, K.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 137 - 137
  • [10] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
    Koji Nishimoto
    Masato Karayama
    Naoki Inui
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Nao Inami
    Shun Matsuura
    Yusuke Kaida
    Takashi Matsui
    Kazuhiro Asada
    Hiroyuki Matsuda
    Masato Fujii
    Mikio Toyoshima
    Shiro Imokawa
    Takafumi Suda
    Medical Oncology, 2018, 35
12345